Yakup Ozsezer, Yildirim B Gulhan, Sibel F Ertan, Akın Akakın, Atilla Yılmaz, Murteza Cakır, Mustafa Ceylan, Onur Yarar and Ozgur Oztop Cakmak
Parkinson disease (PD) represents 75% of all parkinsonian syndromes and is a chronic, slow progressive neurodegenerative disorder. In 2030, the population of PD patients all over the world is expected to reach to 8.7-9.3 million of patients. In 1997, Deep Brain Stimulation (DBS) was firstly approved as an alternative treatment option in PD patients. In Turkey although DBS was reimbursed for the treatment of PD since 2009 , we could not reach out any cost analyze studies. Our primary aim with four different university hospitals 60 patients’ data is to compare the costs of one year best medical treatment and DBS in the first year after its application. Second approach was to evaluate the pre and postoperative conditions via UPDRSIII and Hoehn and Yahr rating scales. Total one-year implantation cost was calculated 58.079,82 TL per case. The cost benefit outcomes were changes in UPDRS III and Hoehn and Yahr after DBS treatment were 7.1 and 1.13 points, respectively. All values have been verified with wilcoxon, friedman and one sample Kolmogorov statistical analyzes. In terms of cost effectiveness and minimization, the result could not be achieved in comparing one-year cost datas. Long term studies involving more centers and patients should be undertaken in future
